Health Partners •••• Medicare

PRIOR AUTHORIZATION REQUEST FORM

Xgeva - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.	
Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: Medicare	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I the life or health of the enrollee or the enrollee's ability to regain maximum funct	certify that applying the 72 hour standard review timeframe may seriously jeopardize ion.
Drug Name:	
Strength: Directions / SIG:	
Directions / Sig:	
	os and information for this member that may support approval.
	lowing questions and sign.
Q1. Is this a continuation? If Yes, go to 16.	□ Na
Yes	☐ No
Q2. Is Xegva being used for the prevention of skeletal-rel with documented bone metastases from solid tumors?	ated events in patients with multiple myeloma and patients
Yes	□ No
Q3. Is Xegva being used in the treatment of adults and sk of bone that is unresectable or where surgical resection is	keletally mature adolescents with documented giant cell tumor is likely to result in severe morbidity?
Yes	□ No
Q4. Is Xegva being used to treat hypercalcemia of malign	nancy refractory to bisphosphonates?
Yes	□ No
Q5. Is there documentation showing a trial of, intolerance	to, or contraindication to zoledronic acid?
Yes	□ No
Q6. Is there documentation of albumin-corrected calcium	greater than 12.5 mg/dL?
Yes	□ No
Q7. Is there documentation of a trial of, intolerance to, or	contraindication to IV bisphosphonates?
☐ Yes	□ No
T. Control of the Con	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners •••• Medicare

PRIOR AUTHORIZATION REQUEST FORM

Xgeva - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
Q8. Is there documentation showing calcium levels were checked, corrected prior to therapy and will be monitored while on therapy?		
☐ Yes	□No	
Q9. Is there documentation showing the patient will be receiving supplementation with calcium and vitamin D?		
☐ Yes	□No	
Q10. Is there documentation showing that an oral exam was done, and appropriate preventive dentistry was done prior to starting treatment?		
☐ Yes	□No	
Q11. Is there documentation showing that the patient is not pregnant or planning to become pregnant while on Xgeva, if applicable?		
☐ Yes	□No	
Q12. Is there documentation showing the patient will be using highly effective contraception during treatment and for at least 5 months after the last dose of Xgeva, if applicable?		
☐ Yes	□No	
Q13. Is the prescriber a Hematologist or Oncologist?		
☐ Yes	□ No	
Q14. Is the patient currently being treated with Prolia?		
☐ Yes	□ No	
Q15. Does the prescriber want to have the medication provided by a pharmacy and covered under Medicare Part D?		
☐ Yes	□No	
Q16. Is the diagnosis hypercalcemia of malignancy refractory to bisphosphonates?		
☐ Yes	□No	
Q17. Is there documentation that the corrected serum calcium is less than 11.5 mg/dL? Documentation must be attached.		
☐ Yes	□No	
Q18. Is there documentation showing improvement or stabilization of disease?		
☐ Yes	□No	
Q19. Does the prescriber want to have the medication provided by a pharmacy and covered under Medicare Part D?		
☐ Yes	□No	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Health Partners •••• Medicare

PRIOR AUTHORIZATION REQUEST FORM

Xgeva - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.		
Patient Name:	Prescriber Name:	
Q20. Additional Information:		
Q21. Duration:		
12 months	Other:	
Prescriber Signature	Date	
	2023 Medicare Prior Authorization Request	